Key result
Preoperative sarcopenia fails to predict overall survival after gastric cancer hepatectomy but links to worse RFS.
Why the study?
The study focused on assessing the role of CT-determined sarcopenia in the prognosis of patients with gastric cancer liver metastases receiving hepatectomy.
Does preoperative sarcopenia predict worse overall survival and recurrence-free survival in patients with gastric cancer liver metastases receiving hepatectomy?
Cohort (n=114)
No
Does preoperative sarcopenia predict worse overall survival and recurrence-free survival in patients with gastric cancer liver metastases receiving hepatectomy?
Hazard Ratio: 1.62 (95% CI 0.57–2.73)
p-value: p=0.330
Preoperative CT-determined sarcopenia is an independent predictor of worse recurrence-free survival in patients with gastric cancer liver metastases undergoing hepatectomy.
Sarcopenia should not yet inform hepatectomy decisions in gastric cancer liver metastases; hypothesis-generating for recurrence-free survival risk stratification.
Background The present work focused on assessing the role of computed tomography (CT)-determined sarcopenia in the prognosis of patients with gastric cancer liver metastases (GCLM) receiving hepatectomy. Methods We analyzed data collected from GCLM cases that underwent hepatectomy between March 2011 and July 2017. The third lumbar vertebra (L3) level skeletal muscle index (SMI) was analyzed by abdominal CT to determine the sarcopenia before surgery. The thresholds for CT-based sarcopenia of sex-specific L3 SMI were ≤ 34.9 cm2/m2 and ≤ 40.8 cm2/m2 for female and male, separately We determined overall survival (OS) and recurrence-free survival (RFS)by univariate and multivariate analyses. Results The cohort enrolled altogether 114 patients with GCLM receiving hepatectomy (average age: 62.6 years, male: 79.8%), and 58 (50.8%) patients had sarcopenia. The mean SMI was 34.2 in patients with sarcopenia compared to 42.7 in patients without sarcopenia (p < 0.001). The 1-, 3-, and 5-year OS rates in patients with GCLM after hepatectomy were 78.1, 43.7, and 34.3%, respectively. The 1-, 3-, and 5-year RFS rates in patients were 49.8, 33.6, and 29.3%, respectively. Sarcopenia was related to an advanced age (≥65.0 years) (p = 0.009), reduced BMI (<18.5 kg/m2) (p < 0.001) and number of liver metastases (>1) (p = 0.025). Sarcopenia had a significant associated with the patterns of recurrence (p < 0.001). In addition, patients with sarcopenia had a significant difference in number of liver metastases in comparison with those without sarcopenia (p = 0.025). We discovered from multivariate analysis that sarcopenia independently predicted RFS [hazard ratio (HR) = 1.76; 95% confidence interval (CI)= 1.18–2.35, p = 0.007]. Nevertheless, sarcopenia was not the prognostic factors that independently predicted OS (HR = 1.62; 95% CI = 0.57–2.73; p = 0.330). Conclusions In conclusion, we showed that CT-determined sarcopenia was the facile and effective prognostic factor for RFS inpatients with GCLM after hepatectomy. Patients with sarcopenia are associated with an increased tumor recurrence risk, and thereby customized treatment should be applied.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2022) conducted a cohort in Gastric cancer liver metastases (n=114). Preoperative sarcopenia vs. No sarcopenia was evaluated on Overall survival (HR 1.62, 95% CI 0.57-2.73, p=0.330). Preoperative sarcopenia did not independently predict overall survival (HR 1.62) in patients with gastric cancer liver metastases undergoing hepatectomy, although it was significantly associated with worse recurrence-free survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: